title: Nuclear DNA content, proliferating-cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions.
abstract: Squamous epithelial cancer in situ (CIS) of the upper aerodigastric tract is a histopathologically well-defined condition. However, in clinical practice, morphological grading of dysplasia is difficult and shows large variability. The biology of CIS remains enigmatic, and there is yet no reliable way to predict whether a CIS lesion will progress to invasive cancer, remain stable or regress. In the search for markers able to foretell clinical outcome, we performed image DNA cytometry (ICM) and immunohistochemical staining for PCNA as well as p53 in 38 laryngeal CIS lesions, of which 9 progressed to invasive cancer. The majority of the CIS lesions displayed high-grade DNA aberration, a high PCNA-positive rate, and every third lesion was p53-positive by immunostaining. The lesions which progressed to invasive cancer showed a clear tendency towards more pronounced DNA aberration, a higher percentage of intense PCNA staining and more frequent p53 positivity. By combining the results from the analyses of DNA, PCNA and p53 in a prognostic index for each individual case, we correctly classified 82% of the lesions as progressors or non-progressors.
authors.affiliation: Department of Oto-rhino-laryngology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Munck-Wikland
authors.forename: S
authors.initials: S
authors.lastname: Edström
authors.forename: E
authors.initials: E
authors.lastname: Jungmark
authors.forename: R
authors.initials: R
authors.lastname: Kuylenstierna
authors.forename: J
authors.initials: J
authors.lastname: Lindholm
authors.forename: G
authors.initials: G
authors.lastname: Auer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D002278:Carcinoma in Situ / Q000737:chemistry* / Q000453:epidemiology / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000453:epidemiology / Q000378:metabolism; D002467:Cell Nucleus / Q000737:chemistry* / Q000378:metabolism; D004273:DNA, Neoplasm / Q000032:analysis* / Q000378:metabolism; D016002:Discriminant Analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000737:chemistry* / Q000453:epidemiology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis* / Q000378:metabolism; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000378:metabolism
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53